Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

By sjmartinez • February 17, 2023

Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, Kuwana M, Stock C, Alves M, Sambevski S, Denton CP. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open. 2023 Feb;9(1):e002859. doi: 10.1136/rmdopen-2022-002859. PMID: 36796874; PMCID: PMC9936273.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Scleroderma, Systemic, Therapeutics

CT Emphysema Subtypes and Cardiac Hemodynamics Estimated on Magnetic Resonance Imaging: The MESA COPD Study

Hermann EA, Yang JX, Angelini E, Balte P, Bluemke DA, Carr J, Derlin K, Gomes AS, Habibi M, Hoffman EA, Johns C, Kawut SM, Kiely[...]

Increased risks of type II diabetes among older Asian, Native Hawaiian, and Pacific Islander lung cancer survivors: a SEER-Medicare analysis

Zhang YF, Chang CE, Varghese TK Jr, Tao R, Hashibe M. Increased risks of type II diabetes among older Asian, Native Hawaiian, and Pacific Islander[...]

Olfaction, Eating Preference, and Quality of Life in Cystic Fibrosis Chronic Rhinosinusitis

Liu CM, Fischer JL, Lee MJ, Mace JC, Kimple AJ, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Chung SY, Eshaghian PH, Gao YA, Getz[...]